IMM2902

IMM2902 is a novel recombinant bispecific fusion protein designed as an immunotherapy for cancer. It combines a SIRPα binding domain with the light chain of a humanized anti-HER2 antibody, creating a HER2/SIRPα bispecific mAb-Trap antibody-receptor fusion protein. The drug targets two key molecules involved in tumor immune evasion and growth: - **HER2 (human epidermal growth factor receptor 2/ERBB2):** Overexpressed in several cancers, including breast and gastric cancers. - **CD47-SIRPα axis:** CD47 acts as a "don't eat me" signal to macrophages; by blocking this interaction via SIRPα, IMM2902 promotes phagocytosis of tumor cells. IMM2902 exerts its antitumor effects through multiple mechanisms: - Antagonism of HER2 signaling to inhibit tumor cell proliferation. - Blockade of CD47-SIRPα interaction to enhance macrophage-mediated phagocytosis. - Stimulation of T lymphocytes and induction of antibody-dependent cellular cytotoxicity (ADCC). Developed using ImmuneOnco's proprietary mAb-Trap platform, it is being evaluated primarily for advanced solid tumors expressing HER2—including breast cancer, gastric cancer, biliary tract cancer, liver cancer, non-small cell lung cancer (NSCLC), ovarian cancer, colon cancer, and urothelial carcinoma. Early clinical data show encouraging safety and preliminary efficacy[1][3][5][6][7][8].

Brand names

IMM2902IMM-2902IMM 2902

Other names

vislarafusp-alfa